Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydrochlorothiazide
Drug ID BADD_D01083
Description Hydrochlorothiazide is the most commonly prescribed thiazide diuretic.[A185138] It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors.[A185138] Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.[L8444]
Indications and Usage Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy.[L8447,L8450] Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.[A185138,L8447,L8450]
Marketing Status approved; vet_approved
ATC Code C03AA03
DrugBank ID DB00999
KEGG ID D00340
MeSH ID D006852
PubChem ID 3639
TTD Drug ID D0U4UQ
NDC Product Code 65862-113; 42708-079; 0172-2089; 50090-1088; 50090-6158; 51655-272; 53002-4970; 57237-002; 62135-448; 63629-1219; 65862-133; 68071-3443; 68071-4963; 68071-5211; 69315-155; 70518-0335; 70518-2540; 70934-916; 71335-1451; 72789-176; 72789-296; 0591-0347; 55488-0300; 42708-028; 50090-6157; 51407-332; 58118-0123; 60687-593; 60687-683; 60760-499; 62135-449; 63187-441; 63629-7782; 63629-8992; 68071-3238; 68071-5284; 68788-8378; 68788-8928; 70934-789; 70934-930; 71205-090; 71205-161; 71610-015; 71610-276; 71610-697; 76282-155; 65862-323; 42708-086; 42708-164; 50090-0724; 53002-4972; 61919-293; 62332-070; 0527-1413; 70518-2629; 71205-793; 71335-0145; 71335-0652; 71335-1481; 71335-9647; 61919-580; 61919-695; 63629-1220; 67296-1487; 67296-1508; 68645-510; 68788-8417; 69584-362; 70518-1676; 71610-261; 72189-263; 57451-1127; 16729-182; 29300-128; 29300-129; 43353-240; 43353-719; 43547-398; 50090-5672; 50090-6156; 51655-088; 51655-502; 51655-616; 0228-2820; 63629-1218; 63629-8991; 68788-6844; 68788-8126; 69584-361; 70518-1728; 70518-2550; 70518-2666; 70934-170; 71335-0770; 0615-8449; 72789-303; 11722-060; 42419-001; 65862-134; 43063-747; 50268-404; 51655-522; 55700-006; 60760-430; 63187-440; 68071-2654; 68071-5266; 69315-130; 70518-3633; 70518-3749; 71205-589; 71205-980; 71335-0269; 12658-0405; 49452-3575; 23155-009; 35356-807; 43063-755; 50090-2744; 50090-6372; 63187-074; 63629-1121; 67296-2043; 67544-739; 68071-5273; 68788-7683; 70518-1595; 71335-1350; 71610-139; 71610-500; 0615-8450; 51927-0172; 51927-1611; 57451-1143; 16729-184; 23155-008; 23155-764; 43547-397; 50090-2727; 50090-5333; 50090-6532; 50228-111; 59746-382; 60760-199; 67296-1274; 68071-2159; 68788-7790; 69315-131; 69367-219; 0527-1414; 70518-0597; 70934-883; 71205-419; 71205-751; 71335-1713; 71610-014; 71610-471; 0615-8149; 12658-0605; 29300-130; 42708-027; 43353-717; 0172-2083; 50090-2706; 51655-674; 53002-1702; 53808-1111; 60760-315; 63187-367; 63187-548; 63629-8498; 68071-2607; 70934-074; 0615-7974; 12828-0008; 62512-0028; 43063-933; 50228-146; 51407-330; 51655-422; 51655-515; 51655-831; 63187-553; 67296-1174; 70518-0210; 70518-1486; 71335-0067; 71335-1976; 71610-488; 76282-154; 12658-0538; 16729-183; 46708-438; 50090-2171; 50228-112; 51407-331
UNII 0J48LPH2TH
Synonyms Hydrochlorothiazide | HCTZ | Dichlothiazide | Dihydrochlorothiazide | HydroDIURIL | Oretic | Sectrazide | Esidrix | Esidrex | Hypothiazide
Chemical Information
Molecular Formula C7H8ClN3O4S2
CAS Registry Number 58-93-5
SMILES C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular fibrillation02.03.04.0080.000030%
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.0020.000037%
Vision blurred06.02.06.007; 17.17.01.0100.000072%
Visual field defect06.02.07.003; 17.17.01.0010.000015%-
Vomiting07.01.07.0030.000239%
Wheezing22.03.01.0090.000015%
Xanthopsia06.02.05.002---
Mental status changes19.07.01.0010.000081%-
Tubulointerstitial nephritis20.05.02.0020.000015%-
Fibromyalgia15.05.02.002---
Peripheral swelling02.05.04.015; 08.01.03.0530.000143%-
General physical health deterioration08.01.03.0180.000061%-
Bradyarrhythmia02.03.02.0150.000030%-
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.0120.000022%-
Lupus-like syndrome10.04.03.003; 15.06.02.004; 23.03.02.004---
Blood pressure inadequately controlled24.06.01.007---
Acute coronary syndrome02.02.02.015; 24.04.04.0110.000010%-
Haemodynamic instability24.03.02.0060.000015%-
Detachment of retinal pigment epithelium06.09.03.0110.000020%-
Musculoskeletal stiffness15.03.05.027---
Epigastric discomfort07.01.02.0040.000030%-
Musculoskeletal discomfort15.03.04.001---
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000152%-
Injection site swelling08.02.03.017; 12.07.03.018---
Type IV hypersensitivity reaction10.01.03.0220.000010%-
Type III immune complex mediated reaction10.01.03.0230.000010%-
Cerebral haematoma17.08.01.014; 24.07.04.0060.000020%-
Fluid intake reduced14.05.10.0010.000032%-
Cutaneous lupus erythematosus10.04.03.007; 15.06.02.007; 23.03.02.0080.000015%-
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene